Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment

被引：57

作者：

Roche-Lestienne, C

Preudhomme, C

机构：

[1] INSERM, Unite 524, F-59045 Lille, France

[2] Ctr Hosp Reg & Univ Lille, Lab Hematol A, F-59037 Lille, France

来源：

SEMINARS IN HEMATOLOGY | 2003年 / 40卷 / 02期

关键词：

D O I：

10.1053/shem.2003.50046

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：80 / 82

页数：3

共 16 条

[1] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[2]

Branford S, 2001, BLOOD, V98, p769A

[3] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[4] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[5]

GORRE EM, 2001, SCIENCE, V293, P2163

[6] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[7]

Hochhaus A, 2001, SCIENCE, V293, P2163

[8] Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation [J].

Hofmann, WK ;

Jones, LC ;

Lemp, NA ;

de Vos, S ;

Gschaidmeier, H ;

Hoelzer, D ;

Ottmann, OG ;

Koeffler, HP .

BLOOD, 2002, 99 (05) :1860-1862

[9] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[10] Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571:: diverse mechanisms of resistance [J].

Mahon, FX ;

Deininger, MWN ;

Schultheis, B ;

Chabrol, J ;

Reiffers, J ;

Goldman, JM ;

Melo, JV .

BLOOD, 2000, 96 (03) :1070-1079

← 1 2 →